Stockscreener 앱 받기
7.17
0.70%
0.05
시간 외 거래:
7.09
-0.08
-1.12%
전일 마감가:
$7.12
열려 있는:
$7.05
하루 거래량:
9,505
Relative Volume:
0.79
시가총액:
$48.63M
수익:
-
순이익/손실:
$-71.37M
주가수익비율:
-0.6652
EPS:
-10.7782
순현금흐름:
$-46.62M
1주 성능:
+1.13%
1개월 성능:
-5.66%
6개월 성능:
-16.63%
1년 성능:
-56.94%
1일 변동 폭
$7.05
$7.17
1주일 범위
$6.92
$7.38
52주 변동 폭
$5.67
$21.98
인스틸 바이오 Stock (TIL) Company Profile
명칭
Instil Bio Inc
전화
(972) 499-3350
주소
3963 MAPLE AVENUE, DALLAS
Compare TIL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
7.17 | 48.63M | 0 | -71.37M | -46.62M | -10.78 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
인스틸 바이오 Stock (TIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-01-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-04-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-01 | 다운그레이드 | Truist | Buy → Hold |
| 2021-08-13 | 개시 | Robert W. Baird | Outperform |
| 2021-04-13 | 개시 | Cowen | Outperform |
| 2021-04-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-04-13 | 개시 | Truist | Buy |
모두보기
인스틸 바이오 주식(TIL)의 최신 뉴스
Trading the Move, Not the Narrative: (TIL) Edition - Stock Traders Daily
Technical Reactions to TIL Trends in Macro Strategies - Stock Traders Daily
TIL Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Stays Pre-RevenueEarnings Cycle Outlook - dars.gov.et
TIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cost PressuresDebt Analysis Report - dars.gov.et
Press Release: Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
(TIL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
TIL Should I Buy - Intellectia AI
Why (TIL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - manilatimes.net
Instil Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Instil Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Instil Bio Reports Second Quarter 2026 Financial Results - Intellectia AI
Instil Bio Reports $4.3 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
Instil Bio, Inc. 2026: Revenue ($4.35M), Net income ($4.3M), EPS ($0.63) — 10-Q Summary - TradingView
Instil Bio reports Q2 2026 net loss $4.3M, cash and marketable securities $69.9M - TradingView
Instil Bio (TIL) slashes R&D spend and leans on Tarzana lease income in Q2 2026 - Stock Titan
Instil Bio expects $69.9M cash to fund plan beyond 2027 - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
Instil Bio (TIL) Dips 2.7% as Shares Hover Near Key SupportJurik MA - vinanet.vn
TIL Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline Execution Takes Center StageEarnings Volatility Report - vinanet.vn
Instil Bio (TIL) Edges Higher: Biotech Stock Holds Above Key SupportInitial Balance - dars.gov.et
Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Instil Bio, Inc. (TIL) And Encourages Investors to Connect - The National Law Review
Instil Bio, Inc. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Instil Bio Inc (TIL) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Instil Bio Q1 2026 Earnings: EPS Miss Reflects Continued Pre-Clinical-Stage InvestmentNew Analyst Coverage - careplusvn.com
TIL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Instil Bio (TIL) Edges Lower Near Key Support LevelsOvervalued Signals - vinanet.vn
Instil Bio Inc (TIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TIL|Instil Bio Inc|Price:7.380|Chg%:-0.030 - TradingKey
Instil Bio Inc (TIL) Balance Sheet - TradingKey
Instil Bio Inc (TIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Instil Bio Inc (TIL) Income Statement - TradingKey
Instil Bio Inc (TIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TIL|Instil Bio Inc|Price:7.130|Chg%:-0.070 - TradingKey
Instil Bio Inc (TIL) Cash Flow - TradingKey
Instil Bio, Inc. Revenue Breakdown – NASDAQ:TIL - TradingView
TIL|Instil Bio Inc|Price:7.430|Chg%:+0.040 - TradingKey
Instil Bio Inc (TIL) Institutional Confidence - TradingKey
Instil Bio Inc (TIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Avoiding Lag: Real-Time Signals in (TIL) Movement - Stock Traders Daily
TIL Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Burn CashBalance Sheet Strength - dars.gov.et
TIL Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues developmentGrowth Acceleration Report - vinanet.vn
TIL Q1 2026 Earnings: EPS Miss Slightly Wider Than Expected Amid Quiet Stock ReactionNegative Surprise Momentum - dars.gov.et
TIL Q1 2026 Earnings: Wider-than-Expected Loss Highlights Ongoing ChallengesEarnings Quality Score - vinanet.vn
Instil Bio Inc. (TIL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Reports Wider Loss - DonanımHaber
Instil Bio (TIL) edges higher as shares test key support-resistance rangeTriangle Correction - DonanımHaber
Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Investors to Inquire about Securities Investigation - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (T - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
인스틸 바이오 (TIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):